[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Guidelines Synopsis
December 3, 2014

Cervical Cancer Screening

Author Affiliations
  • 1Department of Medicine, University of Chicago, Chicago, Illinois

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2014;312(21):2279-2280. doi:10.1001/jama.2014.14992

Approximately 12 000 new cases of cervical cancer are expected to occur in the United States in 2014, with 4000 deaths from the disease.1 Women younger than 50 years have the highest incidence of cervical cancer, and the disease is more prevalent in Hispanic and black women. Fifty percent of women diagnosed with cervical cancer were never screened, and an additional 10% were not screened in the 5-year period before the diagnosis.1 For decades, screening has been performed via cytological examination of cells from the cervical transformation zone (Papanicolaou smear). More recently, testing for HPV, the causative agent in most cases of cervical cancer, has been added as a screening modality.

First Page Preview View Large
First page PDF preview
First page PDF preview